Description
Yuflyma (adalimumab-aaty) is a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-a), a key mediator of inflammatory and immune responses. By blocking the interaction of TNF-a with its receptors, Yuflyma reduces inflammation and immune-mediated tissue damage. It is indicated for the treatment of multiple chronic autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, and uveitis, among others.
Fact Table |
Formula | C6428H9912N1694O1987S46 |
License | US FDA, EMA |
Bioavailability | 64% |
Legal status | Rx-only |
Chemical Name | Adalimumab |
Elimination half-life | 10–20 days |
Dosage (Strength) | 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe or autoinjector |
Pregnancy | Consult a doctor (Category B) |
Brands | Yuflyma (biosimilar to Humira) |
Protein binding | Not applicable (monoclonal antibody) |
PubChem CID | 11959600 |
MedlinePlus | a604006 |
ChEBI | 75475 |
ATC code | L04AB04 |
DrugBank | DB00051 |
KEGG | D06474 |
Routes of administration | Subcutaneous injection |
Directions
Yuflyma is administered by subcutaneous injection, with dosing regimens varying by condition and patient characteristics. For example:
- Rheumatoid arthritis (adults): 40 mg every other week
- Crohn’s disease (adults): 160 mg initially, 80 mg at week 2, then 40 mg every other week
- Plaque psoriasis: 80 mg initial dose, followed by 40 mg every other week starting one week later
Patients may self-administer Yuflyma after proper training. It is available in a prefilled autoinjector or prefilled syringe. The product should be stored refrigerated and brought to room temperature before use. Injection sites (thigh or abdomen) should be rotated with each dose.
Ingredients
Each 0.8 mL of Yuflyma contains:
- L-histidine hydrochloride monohydrate
Yuflyma is citrate-free, latex-free, and preservative-free, which may reduce injection site discomfort.
Contraindications
Yuflyma is contraindicated in patients with:
- Known hypersensitivity to adalimumab or any component of the formulation
- Active tuberculosis, sepsis, or other severe infections
- Moderate to severe heart failure (in certain indications)
Cautions
Before starting Yuflyma, screen patients for latent or active tuberculosis and evaluate for hepatitis B. Monitor throughout therapy for infections, malignancy (especially lymphoma and skin cancers), demyelinating disorders, and cytopenias. Avoid concurrent use with other biologic immunomodulators. Live vaccines should not be given during treatment. Caution is advised in patients with a history of chronic or recurrent infections, or with underlying conditions that predispose them to infection.
Side Effects
Common side effects of Yuflyma include:
- Injection site reactions (pain, redness, swelling)
- Upper respiratory tract infections
Serious adverse effects may include:
- Serious infections (e.g., TB, bacterial sepsis)
- Malignancies (lymphoma, skin cancer)
- Demyelinating disease (e.g., multiple sclerosis-like syndrome)
- Heart failure exacerbation
- Severe hypersensitivity reactions
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14364